BMRN

BioMarin Pharmaceutical Inc.

NASDAQHealthcareBiotechnologyUS

Rating:B+

CEO

Alexander Hardy

IPO Date

1999-07-26

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

News SentimentBullish

Articles

Avg Positive

52.2%

Avg Negative

4.0%

Avg Neutral

43.9%

News Feed

BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe

Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval

European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close